Sinphar Pharmaceutical Co.,Ltd. (1734.TW)
TWD 31.55
(-0.94%)
TWD 31.55
(-0.94%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 582.94 Million TWD | 8.26% |
| 2022 | 539.57 Million TWD | 381.4% |
| 2021 | 109.64 Million TWD | -27.78% |
| 2020 | 157.16 Million TWD | -10.93% |
| 2019 | 173.17 Million TWD | 8.83% |
| 2018 | 171.56 Million TWD | -23.34% |
| 2017 | 206.91 Million TWD | -17.26% |
| 2016 | 246.21 Million TWD | 33.58% |
| 2015 | 188.41 Million TWD | -55.03% |
| 2014 | 420.63 Million TWD | -29.53% |
| 2013 | 596.89 Million TWD | 77.11% |
| 2012 | 328.51 Million TWD | 26.6% |
| 2011 | 266.19 Million TWD | -6.77% |
| 2010 | 282.12 Million TWD | -2.24% |
| 2009 | 293.9 Million TWD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 141.97 Million TWD | -6.18% |
| 2024 Q1 | 151.33 Million TWD | -17.59% |
| 2023 FY | - TWD | 8.26% |
| 2023 Q1 | 161.39 Million TWD | 136.9% |
| 2023 Q2 | 107.48 Million TWD | -33.4% |
| 2023 Q3 | 132.73 Million TWD | 23.49% |
| 2023 Q4 | 183.01 Million TWD | 37.88% |
| 2022 Q3 | 157.93 Million TWD | -10.98% |
| 2022 Q1 | 136.57 Million TWD | 112.76% |
| 2022 FY | - TWD | 381.4% |
| 2022 Q4 | 68.12 Million TWD | -56.86% |
| 2022 Q2 | 177.4 Million TWD | 29.89% |
| 2021 Q4 | 64.19 Million TWD | 176.32% |
| 2021 Q3 | -84.1 Million TWD | -224.49% |
| 2021 FY | - TWD | -27.78% |
| 2021 Q1 | 64.53 Million TWD | 607.1% |
| 2021 Q2 | 67.55 Million TWD | 4.69% |
| 2020 Q4 | -12.72 Million TWD | -135.46% |
| 2020 Q1 | 80.61 Million TWD | -2.91% |
| 2020 Q2 | 51.56 Million TWD | -36.03% |
| 2020 FY | - TWD | -10.93% |
| 2020 Q3 | 35.88 Million TWD | -30.41% |
| 2019 Q4 | 83.02 Million TWD | 251.23% |
| 2019 Q3 | 23.63 Million TWD | 637.31% |
| 2019 FY | - TWD | 8.83% |
| 2019 Q1 | 64.53 Million TWD | 43.25% |
| 2019 Q2 | 3.2 Million TWD | -95.03% |
| 2018 FY | - TWD | -23.34% |
| 2018 Q2 | 42.75 Million TWD | -27.11% |
| 2018 Q1 | 58.65 Million TWD | -13.78% |
| 2018 Q4 | 45.04 Million TWD | 79.44% |
| 2018 Q3 | 25.1 Million TWD | -41.28% |
| 2017 Q1 | 29.5 Million TWD | -78.27% |
| 2017 Q4 | 68.03 Million TWD | 19.15% |
| 2017 Q3 | 57.1 Million TWD | 9.23% |
| 2017 FY | - TWD | -17.26% |
| 2017 Q2 | 52.27 Million TWD | 77.2% |
| 2016 Q3 | 41.27 Million TWD | 1.23% |
| 2016 FY | - TWD | 33.58% |
| 2016 Q4 | 135.76 Million TWD | 228.94% |
| 2016 Q2 | 40.77 Million TWD | 43.56% |
| 2016 Q1 | 28.4 Million TWD | -80.83% |
| 2015 FY | - TWD | -55.03% |
| 2015 Q1 | 2.55 Million TWD | -98.1% |
| 2015 Q2 | 33.17 Million TWD | 1198.08% |
| 2015 Q4 | 148.13 Million TWD | 2408.16% |
| 2015 Q3 | 5.9 Million TWD | -82.2% |
| 2014 Q4 | 134.79 Million TWD | 5786.03% |
| 2014 Q2 | 154.64 Million TWD | 19.96% |
| 2014 Q1 | 128.91 Million TWD | 15.91% |
| 2014 FY | - TWD | -29.53% |
| 2014 Q3 | 2.29 Million TWD | -98.52% |
| 2013 Q1 | 213.54 Million TWD | 186.92% |
| 2013 Q3 | 160.13 Million TWD | 42.97% |
| 2013 Q4 | 111.21 Million TWD | -30.55% |
| 2013 FY | - TWD | 77.11% |
| 2013 Q2 | 112 Million TWD | -47.55% |
| 2012 Q4 | 74.42 Million TWD | -28.8% |
| 2012 Q3 | 104.53 Million TWD | 7.61% |
| 2012 FY | - TWD | 26.6% |
| 2012 Q2 | 97.14 Million TWD | 38.72% |
| 2012 Q1 | 70.02 Million TWD | 13.63% |
| 2011 Q2 | 73.32 Million TWD | 3.21% |
| 2011 Q1 | 71.04 Million TWD | -7.21% |
| 2011 Q3 | 60.19 Million TWD | -17.91% |
| 2011 Q4 | 61.62 Million TWD | 2.38% |
| 2011 FY | - TWD | -6.77% |
| 2010 Q3 | 51.51 Million TWD | -33.8% |
| 2010 FY | - TWD | -2.24% |
| 2010 Q1 | 79.63 Million TWD | 0.0% |
| 2010 Q4 | 76.56 Million TWD | 48.63% |
| 2010 Q2 | 77.81 Million TWD | -2.28% |
| 2009 FY | - TWD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Apex Biotechnology Corp. | 221.06 Million TWD | -163.704% |
| Panion & Bf Biotech Inc. | 327.21 Million TWD | -78.151% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 473.81 Million TWD | -23.032% |
| GenMont Biotech Incorporation | 71.76 Million TWD | -712.26% |
| Abnova (Taiwan) Corporation | 81.2 Million TWD | -617.831% |
| Adimmune Corporation | -512.42 Million TWD | 213.761% |
| Tanvex BioPharma, Inc. | -1.75 Billion TWD | 133.226% |
| Polaris Group | -1.38 Billion TWD | 141.953% |
| Energenesis Biomedical CO.,LTD. | -244.57 Million TWD | 338.347% |
| UnicoCell Biomed Co., Ltd. | -56.27 Million TWD | 1135.864% |
| PELL Bio-Med Technology Co. Ltd. | -353.17 Million TWD | 265.056% |